Latest News in the pharma Industry

Research & Development

Bavarian Nordic and Janssen to develop vaccine regimens against HIV-1 and Hepatitis B

Bavarian Nordic and Janssen to develop vaccine regimens against HIV-1 and Hepatitis B

27 Jul 2017

Deal builds on ongoing collaboration to develop vaccines for Human Papillomavirus (HPV) and Ebola.

Read more 
BMS's Orencia receives second EC approval in less than a year

BMS's Orencia receives second EC approval in less than a year

26 Jul 2017

New approval for treatment of active psoriatic arthritis (PsA).

Read more 
Long-acting injection to remove daily dosing burden for HIV patients?

Long-acting injection to remove daily dosing burden for HIV patients?

24 Jul 2017

Study results showed that long-acting cabotegravir and rilpivirine maintained viral suppression.

Read more 
Lilly backs Nektar Therapeutics' novel immunological therapy

Lilly backs Nektar Therapeutics' novel immunological therapy

24 Jul 2017

NKTR-358 has the potential to treat a number of autoimmune and other chronic inflammatory conditions.

Read more 
Novartis receives positive CHMP opinion for Rydapt

Novartis receives positive CHMP opinion for Rydapt

23 Jul 2017

If approved, Rydapt would represent the first targeted treatment for newly diagnosed FLT3-mutated AML in the EU.

Read more 
Catalent and academia on quest to better understand pediatric drug formulation and delivery challenges

Catalent and academia on quest to better understand pediatric drug formulation and delivery challenges

20 Jul 2017

Goal of the collaboration is to identify therapies and diseases for which there is a high need for pediatric-friendly formulations.

Read more 
Positive results from 12-month Phase III safety study of Revefenacin in patients with COPD

Positive results from 12-month Phase III safety study of Revefenacin in patients with COPD

20 Jul 2017

These data, combined with positive results from two Phase III efficacy studies, support NDA filing planned for fourth quarter of 2017.

Read more 
Onyx helps to accelerate TopiVert’s compounds to clinic

Onyx helps to accelerate TopiVert’s compounds to clinic

19 Jul 2017

With support from the CRO, TopiVert has been able to accelerate scale-up and produce GMP batches, which are now being used in clinical trials.

Read more 
Shire expands broad monoclonal antibody research platform

Shire expands broad monoclonal antibody research platform

18 Jul 2017

Shire obtains worldwide license to pursue development and commercialization of a novel, potentially differentiated, pre-clinical bi-specific antibody candidate for Hemophilia A.

Read more 
Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

18 Jul 2017

Array to advance preclinical program for autoimmune disorders; Amgen responsible for clinical development and worldwide commercialization.

Read more 
Alzheon presents new data for ALZ-801 on novel MOA and long-term clinical efficacy at the AAIC

Alzheon presents new data for ALZ-801 on novel MOA and long-term clinical efficacy at the AAIC

17 Jul 2017

Presentations highlight recent discovery of inhibition of formation of toxic beta amyloid oligomers and new insights for Precision Medicine approach for ALZ-801 targeting APOE4 carriers.

Read more 
Ground-breaking preclinical data to be presented at AAIC 2017

Ground-breaking preclinical data to be presented at AAIC 2017

16 Jul 2017

KalGene’s Alzheimer’s therapeutics candidate, licensed from the NRC (KAL-ABP-BBB), crosses the blood-brain barrier, and reduces amyloid-beta burden in a transgenic rat model after a 4-week treatment.

Read more